Combination targeted drug and immunotherapy for recurrent gynecologic cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have squamous cell carcinoma of the cervix, vagina, or vulva that has come back or spread to other parts of the body.
- You have already tried at least one standard treatment that included platinum chemotherapy and an immunotherapy drug, and you have not had more than 4 prior treatments.
- You are able to take care of yourself and are up and about more than half of the day (ECOG 0 or 1).
- Your cancer has at least one tumor that can be measured on a scan.
- You are not pregnant, are not breastfeeding, and agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial tests a new drug combo—becotatug vedotin plus a PD-1 inhibitor—for people with head and neck squamous cell cancer that cannot be surgically removed. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests adding the immunotherapy drug Zimberelimab to standard chemoradiation after surgery for locally advanced cervical cancer. It aims to see if this combination helps prevent the cancer from coming back.
This trial tests two new drugs (becotatug vedotin and pucotenlimab) together for advanced biliary tract cancer—a cancer of the bile ducts or gallbladder. The drugs may help if your cancer has a specific marker (EGFR) and has not responded to earlier treatments.
This trial tests a new drug (Becotatug Vedotin) combined with standard chemotherapy and radiation for locally advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective.
Hear when a new Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.